TY  - JOUR
AU  - Guerra Veloz, María Fernanda
AU  - Vázquez Morón, Juan María
AU  - Belvis Jiménez, María
AU  - Pallarés Manrique, Héctor
AU  - Valdés Delgado, Teresa
AU  - Castro Laria, Luisa
AU  - Maldonado Pérez, Belén
AU  - Benítez Roldán, Antonio
AU  - Perea Amarillo, Raúl
AU  - Merino, Vicente
AU  - Caunedo Álvarez, Ángel
AU  - Argüelles Arias, Federico
PY  - 2018
DO  - 10.17235/reed.2018.5368/2017
SN  - 1130-0108
UR  - http://hdl.handle.net/10668/12580
T2  - Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
AB  - infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of biosimilar treatments such as CT-P13 will hopefully improve the availability of biological therapies. Data with regard to drug switching are currently...
LA  - en
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - Colitis, Ulcerative
KW  - Crohn Disease
KW  - Female
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Inflammatory Bowel Diseases
KW  - Infliximab
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Treatment Outcome
TI  - Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
TY  - research article
VL  - 110
ER  -